Myth and Truth About Off-Label Use of Antidepressants

Understanding Antidepressants

Antidepressants are primarily utilized to treat depression, but their use extends beyond this singular condition. They are frequently prescribed for various mental health issues, including anxiety disorders, eating disorders, sleep disturbances, and obsessive-compulsive disorder. Additionally, there are instances where antidepressants are prescribed for non-mental health conditions, such as menopausal symptoms, fibromyalgia, and chronic neuropathic pain.

Research Findings on Off-Label Use

Despite the growing trend of off-label prescribing of antidepressants, a recent study published in the British Medical Journal challenges the validity of this practice. The study examined 106,850 antidepressant prescriptions issued by 174 physicians in Quebec, Canada, focusing on the conditions for which these medications were prescribed and the scientific research backing these prescriptions.

The findings revealed that tricyclic antidepressants were the most frequently prescribed for off-label uses. However, it was noted that only 16% of off-label cases had strong scientific support. Even more striking was the discovery that in instances lacking evidence for off-label use, 40% had supporting research for another antidepressant within the same class that could effectively treat the condition.

Conclusion

The current evidence suggests a significant gap in the scientific backing for off-label antidepressant prescriptions. For a deeper understanding of this issue, refer to the study conducted by Wong et al., titled “Off-label indications for antidepressants in primary care: Descriptive study of prescriptions from an indication based electronic prescribing system,” published in the BMJ.

Reference

Wong J, Motulsky A, Abrahamowicz M, Eguale T, Buckeridge DL, Tamblyn R. Off-label indications for antidepressants in primary care: Descriptive study of prescriptions from an indication based electronic prescribing system. BMJ. Published online 2017. doi:10.1136/bmj.j603